Article

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection

2021-06-09

Abstract excerpt

Despite recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both, prophylactic and therapeutic drugs....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4260245a-7888-504e-9a77-fd82deb53510
DOI: 10.1101/2021.06.09.447662

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infectionDOI 10.1101/2021.06.09.447662Read

SARS-CoV-2 neutralization and protection of hamsters via nasal administration of a humanized neutralizing antibodySemantic proximity Read

Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanismSemantic proximity Read

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administrationSemantic proximity Read

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibodySemantic proximity Read

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike proteinSemantic proximity Read

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster modelSemantic proximity Read

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19Semantic proximity Read

Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect <i>in vivo</i> in a mouse model in a neutralization dependent mannerSemantic proximity Read

Intranasal inhibitor broadly blocks SARS-CoV-2 including recent highly immunoevasive Omicron subvariantsSemantic proximity Read

Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol deliverySemantic proximity Read

AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In VivoSemantic proximity Read

A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccinationSemantic proximity Read